ArticleDiabetology & metabolic syndrome2025
Temporal dynamic of cognitive decline in type 2 diabetes mellitus patients: a multimodal biomarker analysis using event-based modal and principal component analysis.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trajectory-Oriented Brain Vulnerability Framework for Cognitive Decline in Type 2 Diabetes.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundType 2 diabetes mellitus (T2DM) is an important risk factor for cognitive impairment. Prior research has shown cognitive deficits and neural alterations across multiple domains in T2DM patients. However, the sequential dynamics of cognitive decline in this population remain poorly understood. This study employs an integrative approach combining Principal Component Analysis (PCA) and the Event-Based Model (EBM) to identify the temporal sequence of cognitive changes and underlying neural mechanisms in T2DM.
methodsThis study assessed 119 T2DM patients and 87 healthy controls with neuropsychological tests and Magnetic Resonance Imaging for gray matter volume (GMV). PCA was used to reduce dimensionality in CVLT, STROOP, and WCST due to their substantial number of items, enabling integration into the EBM model. EBM estimated the sequence of cognitive and neurostructural changes. Partial correlation analyses were used to examine associations with clinical factors with controlling covariance.
resultsCognitive decline in T2DM began with attention and working memory, followed by executive function and episodic memory. GMV loss started in the insular gyrus, spreading to other regions. T2DM patients exhibited significantly more advanced disease progression than healthy controls (EBM stage 0.54 (0.12) vs. 0.49 (0.10), P = 0.001). A negative correlation linked long-delay memory (CVLT-PC4) to random blood glucose (r = -0.581, P
conclusionMemory decline and insular gyrus atrophy may serve as early biomarkers for T2DM-related cognitive impairment. These findings highlight potential targets for early intervention and suggest strategies for developing personalized treatments to improve life quality in affected individuals.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.